400 related articles for article (PubMed ID: 17875341)
21. Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients.
Guadagni F; Ferroni P; Basili S; Facciolo F; Carlini S; Crecco M; Martini F; Spila A; D'Alessandro R; Aloe S; Cerasoli V; Del Monte G; Mariotti S; Mineo TC; Roselli M
Lung Cancer; 2004 Jun; 44(3):303-10. PubMed ID: 15140543
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
23. Serum endostatin levels in patients with lung carcinoma.
Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
[TBL] [Abstract][Full Text] [Related]
24. Utility of plasma tumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma.
Kumar S; Guleria R; Mohan A; Singh V; Ali A; Bharti AC; Das BC
Biomarkers; 2010 Aug; 15(5):446-53. PubMed ID: 20486867
[TBL] [Abstract][Full Text] [Related]
25. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.
Moon YW; Choi SH; Kim YT; Sohn JH; Chang J; Kim SK; Park MS; Chung KY; Lee HJ; Kim JH
Cancer; 2007 May; 109(9):1829-35. PubMed ID: 17366594
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
[TBL] [Abstract][Full Text] [Related]
29. Osteopontin as a marker of weight loss in lung cancer.
Karadag F; Gulen ST; Karul AB; Kilicarslan N; Ceylan E; Kuman NK; Cildag O
Scand J Clin Lab Invest; 2011 Dec; 71(8):690-4. PubMed ID: 22017168
[TBL] [Abstract][Full Text] [Related]
30. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
31. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.
Shinohara ET; Gonzalez A; Massion PP; Chen H; Li M; Freyer AS; Olson SJ; Andersen JJ; Shyr Y; Carbone DP; Johnson DH; Hallahan DE; Lu B
Cancer; 2005 Apr; 103(8):1685-92. PubMed ID: 15742356
[TBL] [Abstract][Full Text] [Related]
32. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
Gautschi O; Bigosch C; Huegli B; Jermann M; Marx A; Chassé E; Ratschiller D; Weder W; Joerger M; Betticher DC; Stahel RA; Ziegler A
J Clin Oncol; 2004 Oct; 22(20):4157-64. PubMed ID: 15483026
[TBL] [Abstract][Full Text] [Related]
33. Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression.
Kanoh Y; Ohara T; Mashiko T; Abe T; Masuda N; Akahoshi T
Anticancer Res; 2006; 26(6B):4293-7. PubMed ID: 17201147
[TBL] [Abstract][Full Text] [Related]
34. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.
Huang CL; Liu D; Nakano J; Yokomise H; Ueno M; Kadota K; Wada H
Clin Cancer Res; 2007 Dec; 13(23):6938-46. PubMed ID: 18056168
[TBL] [Abstract][Full Text] [Related]
35. Cytokeratin 8 and 18 fragments measured in serum and their relation to survival in patients with non-small cell lung cancer.
Bergqvist M; Brattström D; Hesselius P; Wiklund B; Silen A; Wagenius G; Brodin O
Anticancer Res; 1999; 19(3A):1833-6. PubMed ID: 10470123
[TBL] [Abstract][Full Text] [Related]
36. Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer.
Park JH; Choi H; Kim YB; Kim YS; Sheen SS; Choi JH; Lee HL; Lee KS; Chung WY; Lee S; Park KJ; Hwang SC; Lee KB; Park KJ
Lung Cancer; 2009 Dec; 66(3):359-64. PubMed ID: 19339077
[TBL] [Abstract][Full Text] [Related]
37. Mental state as a possible independent prognostic variable for survival in patients with advanced lung carcinoma.
Nakahara Y; Mochizuki Y; Miyamoto Y; Tanaka A; Kawamura T; Sasaki S; Nakahara Y; Katsura Y
Cancer; 2002 Jun; 94(11):3006-15. PubMed ID: 12115391
[TBL] [Abstract][Full Text] [Related]
38. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
[TBL] [Abstract][Full Text] [Related]
40. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients.
El-Akawi ZJ; Abu-Awad AM; Sharara AM; Khader Y
Neuro Endocrinol Lett; 2010; 31(1):113-6. PubMed ID: 20150872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
